NASDAQ:EOLS Evolus Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Evolus Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.87 +0.03 (+0.78 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$3.70Now: $3.87▼$3.9150-Day Range$3.03MA: $3.62▼$4.0452-Week Range$3.00Now: $3.87▼$19.00Volume298,527 shsAverage Volume372,052 shsMarket Capitalization$130.61 millionP/E RatioN/ADividend YieldN/ABeta2.83 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California. Evolus, Inc. is a subsidiary of ALPHAEON Corporation.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingEvolus has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.43, Evolus has a forecasted upside of 143.6% from its current price of $3.87.Amount of Analyst CoverageEvolus has only been the subject of 3 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesEvolus has received 303 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEvolus has received 232 “underperform” votes. (Add your “underperform” vote.)Community SentimentEvolus has received 56.64% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Evolus and other stocks. Vote “Outperform” if you believe EOLS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EOLS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEvolus does not currently pay a dividend.Dividend GrowthEvolus does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evolus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.10% of the stock of Evolus is held by insiders.Percentage Held by InstitutionsOnly 27.52% of the stock of Evolus is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Evolus are expected to grow in the coming year, from ($2.09) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evolus is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evolus is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvolus has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.33 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EOLS Previous Symbol CUSIPN/A CIK1570562 Webwww.evolus.com Phone949-284-4555Debt Debt-to-Equity Ratio1.78 Current Ratio5.55 Quick Ratio5.02Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$34.92 million Price / Sales3.74 Cash FlowN/A Price / Cash FlowN/A Book Value$2.38 per share Price / Book1.63Profitability EPS (Most Recent Fiscal Year)($3.19) Net Income$-90,030,000.00 Net Margins-161.74% Return on Equity-162.50% Return on Assets-39.60%Miscellaneous Employees70 Outstanding Shares33,750,000Market Cap$130.61 million Next Earnings Date11/2/2020 (Estimated) OptionableOptionable $3.87 +0.03 (+0.78 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive EOLS News and Ratings via Email Sign-up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Evolus (NASDAQ:EOLS) Frequently Asked Questions How has Evolus' stock been impacted by COVID-19? Evolus' stock was trading at $5.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EOLS shares have decreased by 34.5% and is now trading at $3.87. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Evolus? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Evolus. When is Evolus' next earnings date? Evolus is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020. View our earnings forecast for Evolus. How were Evolus' earnings last quarter? Evolus Inc (NASDAQ:EOLS) announced its quarterly earnings data on Monday, May, 11th. The company reported ($0.75) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.72) by $0.03. The business had revenue of $10.50 million for the quarter, compared to analysts' expectations of $16.91 million. Evolus had a negative net margin of 161.74% and a negative return on equity of 162.50%. View Evolus' earnings history. What price target have analysts set for EOLS? 7 brokers have issued 12-month price targets for Evolus' stock. Their forecasts range from $3.00 to $25.00. On average, they anticipate Evolus' stock price to reach $9.43 in the next year. This suggests a possible upside of 143.6% from the stock's current price. View analysts' price targets for Evolus. Who are some of Evolus' key competitors? Some companies that are related to Evolus include Odonate Therapeutics (ODT), Homology Medicines (FIXX), IVERIC bio (ISEE), CymaBay Therapeutics (CBAY), MannKind (MNKD), Urogen Pharma (URGN), Altimmune (ALT), Beyondspring (BYSI), Syros Pharmaceuticals (SYRS), Forte Biosciences (FBRX), Avid Bioservices (CDMO), Kala Pharmaceuticals (KALA), AnaptysBio (ANAB), Passage Bio (IMRA) and Inventiva (IVA). View all competitors. What other stocks do shareholders of Evolus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), Chesapeake Energy (CHKAQ), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Dynavax Technologies (DVAX), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), OrganiGram (OGI) and BioNano Genomics (BNGO). Who are Evolus' key executives? Evolus' management team includes the following people: Mr. David Moatazedi, Pres, CEO & Director (Age 41)Ms. Lauren P. Silvernail, CFO & Exec. VP of Corp. Devel. (Age 60)Mr. Michael Mazen Jafar, Chief Marketing Officer (Age 38)Mr. Alejandro Sabad, VP of OperationsMr. Ashwin K. Agarwal, VP of Fin., Investor Relations & Treasury When did Evolus IPO? (EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. What is Evolus' stock symbol? Evolus trades on the NASDAQ under the ticker symbol "EOLS." Who are Evolus' major shareholders? Evolus' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Laidlaw Wealth Management LLC (2.51%), Alyeska Investment Group L.P. (0.99%), Bank of New York Mellon Corp (0.25%), Nuveen Asset Management LLC (0.21%), Virtu Financial LLC (0.21%) and UBS Group AG (0.19%). Company insiders that own Evolus stock include Corp Alphaeon, David N Gill, Kristine Romine, Lauren P Silvernail, Rui Avelar, Simone Blank and Vikram Malik. View institutional ownership trends for Evolus. Which major investors are selling Evolus stock? EOLS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., and Nuveen Asset Management LLC. View insider buying and selling activity for Evolus. Which major investors are buying Evolus stock? EOLS stock was acquired by a variety of institutional investors in the last quarter, including Laidlaw Wealth Management LLC, Virtu Financial LLC, Alyeska Investment Group L.P., Jefferies Group LLC, Laidlaw Wealth Management LLC, PDT Partners LLC, Advisor Group Holdings Inc., and Algert Global LLC. Company insiders that have bought Evolus stock in the last two years include David N Gill, Kristine Romine, Simone Blank, and Vikram Malik. View insider buying and selling activity for Evolus. How do I buy shares of Evolus? Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Evolus' stock price today? One share of EOLS stock can currently be purchased for approximately $3.87. How big of a company is Evolus? Evolus has a market capitalization of $130.61 million and generates $34.92 million in revenue each year. The company earns $-90,030,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Evolus employs 70 workers across the globe. What is Evolus' official website? The official website for Evolus is www.evolus.com. How can I contact Evolus? Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
